MapLight Therapeutics
Last verified 2026-05-26. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $500.0Mattributed |
|---|---|
| Latest round | series-b, $372.5M, 2025-07-15attributed |
| Founded | 2016 |
| Headquarters | Mountain View |
| Industry | healthcare |
| Stage | series-b+ |
| Website | maplightbio.com |
MapLight Therapeutics is a clinical-stage biotech applying circuit-level neuroscience to develop targeted treatments for brain and nervous system disorders. It serves patients with conditions including schizophrenia and Alzheimer's psychosis, led by ML-007C-MA. Its platform combines optogenetics and transcriptomics to pinpoint misfiring circuits.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-15 | series-b | $372.5M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $372.5M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $500.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | maplightbio.com, read 2026-05-26 |
| Description | self-reported | maplightbio.com, read 2026-05-26 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.